Clinical trial

Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease…

NCT00234871 · Abbott, Industry · Completed

Key facts

NCT number NCT00234871
Title Tarka® vs. Lotrel® in Hypertensive, Diabetic Subjects With Renal Disease (TANDEM)
Official title A Phase IV, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects With Diabetic Nephropathy
Acronym TANDEM
Lead sponsor Abbott, Industry
Status Completed
Phase Phase 4
Study type Interventional
Conditions Hypertension, Diabetes, Proteinuria
Intervention type Drug
Interventions trandolapril/verapamil, Lotrel (amlodipine/benazepril)
Enrollment 357
Start date Jan 1, 2004
Primary completion Mar 1, 2005
First posted Oct 10, 2005
Last update posted Jul 15, 2008

At a glance

  • No Results posted
  • None Linked FDA submissions

Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.

About ClinicalTrials.gov studies

ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.

Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date:

Browse all ClinicalTrials.gov studies